Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2016 Aug;48(8):1197-1207.
doi: 10.1007/s11255-016-1299-7. Epub 2016 May 9.

The augmented prophylactic antibiotic could be more efficacious in patients undergoing transrectal prostate biopsy: a systematic review and meta-analysis

Lu Yang  1 , Zhuang Tang  1 , Liang Gao  1 , Tao Li  1 , Yongji Chen  1 , Liangren Liu  1 , Ping Han  1 , Xiang Li  1 , Qiang Dong  2 , Qiang Wei  3
Affiliations
Meta-Analysis

The augmented prophylactic antibiotic could be more efficacious in patients undergoing transrectal prostate biopsy: a systematic review and meta-analysis

Lu Yang et al. Int Urol Nephrol. 2016 Aug.

Abstract

Background: Although frequent use of prophylactic antibiotics for patients undergoing transrectal prostate biopsy (TRPB), incidences of urinary tract infection (UTI) and bacterial resistance are still increasing. We evaluated the efficacy of augmented prophylactic antibiotics in patients undergoing TRPB.

Methods: A systematic search of Embase(®), PubMed(®), and the Cochrane Library was executed to identify all eligible studies that compared the effects of augmented antibiotic prophylaxis (combined drugs) with single antibiotic prophylaxis on behalf of patients undergoing TRPB. Outcomes qualified in this review included bacteriuria, bacteremia, drug-resistant bacteria on urine culture, drug-resistant bacteria on blood culture, fever, UTI, sepsis, and hospitalization.

Results: A total of eight publications were identified and included in the review, including three randomized controlled trials with 659 patients and five case-control studies involving 3404 patients. All outcomes, including bacteriuria [relative risk (RR) 4.25, 95 % confidence interval (CI) 1.96-9.22, P = 0.0003], bacteremia (RR 4.96, 95 % CI 2.31-10.67, P < 0.0001), drug-resistant bacteriuria (RR 3.52, 95 % CI 1.41-8.78, P = 0.007), drug-resistant bacteremia (RR 4.94, 95 % CI 2.17-11.24, P = 0.0001), fever (RR 2.75, 95 % CI 1.63-4.62, P = 0.0001), UTI (RR 3.76, 95 % CI 2.57-5.48, P < 0.00001), and hospitalization (RR 3.90, 95 % CI 2.64-5.75, P < 0.00001) significantly favored the augmented antibiotic use.

Conclusions: One additional type of antibiotic (usually one single dose) added to the basic antibiotic prophylaxis modality, defined as augmented prophylaxis, could contribute to the reduction in severe infection and drug resistance, particularly in high-risk patients.

Keywords: Antibiotic prophylaxis; Antibiotic resistance; Augmented prophylaxis; Prostate biopsy; Urinary tract infection.

PubMed Disclaimer

References

    1. J Urol. 2011 Apr;185(4):1181-3 - PubMed
    1. J Urol. 2011 Apr;185(4):1283-8 - PubMed
    1. Urology. 2011 Sep;78(3):511-4 - PubMed
    1. Urology. 1998 Oct;52(4):552-8 - PubMed
    1. Int Urol Nephrol. 2012 Aug;44(4):1065-70 - PubMed

LinkOut - more resources